Avanos Medical, Inc.
Avanos Medical, Inc., headquartered in the United States, is a prominent player in the medical device industry, specialising in innovative solutions for pain management and surgical care. Founded in 2014, the company has rapidly established itself as a leader in its field, focusing on advanced technologies that enhance patient outcomes and streamline healthcare processes. With a diverse portfolio that includes products for pain management, wound care, and respiratory health, Avanos Medical distinguishes itself through its commitment to quality and innovation. The company operates in key regions across North America and Europe, ensuring a broad reach in delivering its unique offerings. Notable achievements include significant advancements in regional anaesthesia and the development of proprietary devices that improve procedural efficiency. Avanos Medical continues to solidify its market position by prioritising patient-centric solutions and fostering strong partnerships within the healthcare community.
DitchCarbon Score
How does Avanos Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Avanos Medical, Inc.'s score of 30 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Avanos Medical, Inc.'s reported carbon emissions
In 2024, Avanos Medical, Inc. reported total carbon emissions of approximately 14,112,150 kg CO2e, with Scope 1 emissions at about 1,458,070 kg CO2e and Scope 2 emissions at approximately 12,654,080 kg CO2e. This represents a slight decrease from 2023, where total emissions were about 14,457,820 kg CO2e, with Scope 1 emissions of approximately 1,786,730 kg CO2e and Scope 2 emissions of about 12,671,090 kg CO2e. Over the years, Avanos has demonstrated a commitment to reducing its carbon footprint, with total emissions in 2021 recorded at approximately 11,695,770 kg CO2e, indicating a significant reduction in emissions over the three-year period. However, the company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Avanos Medical's emissions data highlights its focus on managing Scope 1 and Scope 2 emissions, while there is currently no available data on Scope 3 emissions. The company continues to work towards enhancing its sustainability practices in alignment with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 229,240 | 0,000,000 | 0,000,000 |
| Scope 2 | 11,466,530 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Avanos Medical, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
